DRUG INTERACTIONS

Avoid use of tadalafil tablets [see Use in Specific Populations ( 8.7)] .2.4 Dose Adjustment for Use with RitonavirCo-administration of Tadalafil Tablets in Patients on RitonavirIn patients receiving ritonavir for at least one week, start tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions ( 7.5) and Clinical Pharmacology ( 12.3)] .Co-administration of Ritonavir in Patients on Tadalafil TabletsAvoid use of tadalafil tablets during the initiation of ritonavir. Stop tadalafil tablets at least 24 hours prior to starting ritonavir.

After at least one week following the initiation of ritonavir, resume tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions ( 7.5) and Clinical Pharmacology ( 12.3)] . The recommended dose of Tadalafil tablets is 40 mg (two 20 mg tablets) taken once daily with or without food. Dividing the dose (40 mg) over the course of the day is not recommended. Mild (creatinine clearance 51 to 80 mL/min) or moderate (creatinine clearance 31 to 50 mL/min): Start dosing at 20 mg once daily.

Special Cases

Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions ( 6.2)] . Tadalafil is also marketed for erectile dysfunction. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors. There have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. Increase to 40 mg once daily based on individual tolerability. Severe (creatinine clearance <30 mL/min and on hemodialysis): Avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Use in Specific Populations ( 8.6)] . Mild or moderate (Child Pugh Class A or B): Because of limited clinical experience in patients with mild to moderate hepatic cirrhosis, consider a starting dose of 20 mg once per day. Severe (Child Pugh Class C): Patients with severe hepatic cirrhosis have not been studied. Avoid use of tadalafil tablets [see Use in Specific Populations ( 8.7)] .

Co-administration of Tadalafil Tablets in Patients on Ritonavir In patients receiving ritonavir for at least one week, start tadalafil tablets at 20 mg once daily. Co-administration of Ritonavir in Patients on Tadalafil Tablets Avoid use of tadalafil tablets during the initiation of ritonavir. 4 CONTRAINDICATIONS 4.1 Concomitant Organic NitratesTadalafil is contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. Do not use nitrates within 48 hours of the lst dose of tadalafil. Tadalafil generic cialis 10 pills potentiates the hypotensive effect of nitrates. This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway [see Clinical Pharmacology ( 12.2)] .4.2 Concomitant Guanylate Cyclase (GC) StimulatorsCoadministration of GC stimulators, such as riociguat with tadalafil is contraindicated. Tadalafil may potentiate the hypotensive effects of GC stimulators.4.3 Hypersensitivity ReactionsTadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (Tadalafil tablets). Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis [see Adverse Reactions ( 6.2)] .

Comparing Which Lasts Longer

4 CONTRAINDICATIONS 4.1 Concomitant Organic NitratesTadalafil is contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. Do not use nitrates within 48 hours of the lst dose of tadalafil. Tadalafil generic cialis 10 pills potentiates the hypotensive effect of nitrates. This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway [see Clinical Pharmacology ( 12.2)] .4.2 Concomitant Guanylate Cyclase (GC) StimulatorsCoadministration of GC stimulators, such as riociguat with tadalafil is contraindicated. Tadalafil may potentiate the hypotensive effects of GC stimulators.4.3 Hypersensitivity ReactionsTadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (Tadalafil tablets).

Serious side effects of tadalafil

Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis [see Adverse Reactions ( 6.2)] . Tadalafil is contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway [see Clinical Pharmacology ( 12.2)] . Coadministration of GC stimulators, such as riociguat with tadalafil is contraindicated. Tadalafil may potentiate the hypotensive effects of GC stimulators.

Comparison with actions of other PDE5 inhibitors

Tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (Tadalafil tablets). 5 WARNINGS AND PRECAUTIONS 5.1 HypotensionTadalafil has vasodilatory properties that may result in transient decreases in blood pressure. Prior to prescribing tadalafil tablets, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects. Patients with preexisting hypotension,with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators.5.2 Worsening Pulmonary Vascular Occlusive DiseasePulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of tadalafil tablets to patients with veno-occlusive disease, administration of tadalafil tablets to such patients is not recommended. Tadalafil is contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway [see Clinical Pharmacology ( 12.2)] . Coadministration of GC stimulators, such as riociguat with tadalafil is contraindicated. Tadalafil may potentiate the hypotensive effects of GC stimulators. Tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (Tadalafil tablets).

• The yellow Cialis pill can be taken with or without food for convenience.
• Some yellow Cialis pills come in 10mg or 20mg doses for different needs.
• The yellow color indicates a specific formulation of tadalafil medication.
• Cialis's molecular structure is designed to relax penile blood vessels.
• The yellow Cialis pill can be part of a treatment plan for ED.
• Proper dosage of yellow Cialis ensures minimal side effects.
• The yellow Cialis pill is a popular choice worldwide for ED treatment.
• Combining yellow Cialis with certain medications can be dangerous.
• Levitra and Viagra are other ED medications often compared with Cialis.
• Using yellow Cialis in excess can lead to dangerous health complications.
• Yellow Cialis pills are sometimes used by men seeking longer-lasting solutions.
• Always buy yellow Cialis from reputable sources to avoid counterfeit products.

5 WARNINGS AND PRECAUTIONS 5.1 HypotensionTadalafil has vasodilatory properties that may result in transient decreases in blood pressure. Prior to prescribing tadalafil tablets, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects. Patients with preexisting hypotension,with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators.5.2 Worsening Pulmonary Vascular Occlusive DiseasePulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD).

5.1 Cardiovascular

Avoid use of tadalafil tablets [see Use in Specific Populations ( 8.7)] .2.4 Dose Adjustment for Use with RitonavirCo-administration of Tadalafil Tablets in Patients on RitonavirIn patients receiving ritonavir for at least one week, start tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions ( 7.5) and Clinical Pharmacology ( 12.3)] .Co-administration of Ritonavir in Patients on Tadalafil TabletsAvoid use of tadalafil tablets during the initiation of ritonavir. Stop tadalafil tablets at least 24 hours prior to starting ritonavir. After at least one week following the initiation of ritonavir, resume tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions ( 7.5) and Clinical Pharmacology ( 12.3)] .

Food interactions

The recommended dose of Tadalafil tablets is 40 mg (two 20 mg tablets) taken once daily with or without food. Dividing the dose (40 mg) over the course of the day is not recommended. Mild (creatinine clearance 51 to 80 mL/min) or moderate (creatinine clearance 31 to 50 mL/min): Start dosing at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability. Severe (creatinine clearance <30 mL/min and on hemodialysis): Avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Use in Specific Populations ( 8.6)] .

Driving or using machines

Mild or moderate (Child Pugh Class A or B): Because of limited clinical experience in patients with mild to moderate hepatic cirrhosis, consider a starting dose of 20 mg once per day. Severe (Child Pugh Class C): Patients with severe hepatic cirrhosis have not been studied. Avoid use of tadalafil tablets [see Use in Specific Populations ( 8.7)] . Co-administration of Tadalafil Tablets in Patients on Ritonavir In patients receiving ritonavir for at least one week, start tadalafil tablets at 20 mg once daily. Co-administration of Ritonavir in Patients on Tadalafil Tablets Avoid use of tadalafil tablets during the initiation of ritonavir. Since there are no clinical data on administration of tadalafil tablets to patients with veno-occlusive disease, administration of tadalafil tablets to such patients is not recommended.

17.10 Sexually Transmitted Disease

6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling:Hypotension [see Warnings and Precautions ( 5.1)]Visual Loss [see Warnings and Precautions ( 5.3) and Patient Counseling Information ( 17)]Hearing loss [see Warnings and Precautions ( 5.4)]Priapism [see Warnings and Precautions ( 5.6)]6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. In trials of tadalafil tablets, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. The overall rates of discontinuation because of an adverse event (AE) in the placebo-controlled trial were 9% for tadalafil tablets 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil tablets 40 mg was 4% compared to 5% in placebo-treated patients.In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of tadalafil. Should signs of pulmonary edema occur when tadalafil tablets are administered, the possibility of associated PVOD should be considered.5.3 Visual LossWhen used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including tadalafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking. Based on published literature, the annual incidence of NAION is 2.5 to 11.8 cases per 100,000 in males aged ≥50 in the general population. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, typical of erectile dysfunction treatment, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended.5.4 Hearing ImpairmentCases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions ( 6.2)] .5.5 Combination with Other PDE5 InhibitorsTadalafil is also marketed for erectile dysfunction. The safety and efficacy of taking tadalafil tablets together with another PDE5 inhibitors has not been studied. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors.5.6 Prolonged ErectionThere have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. Patients who have conditions that might predispose them to priapism (such as without prescription cialis soft sickle cell anemia, multiple myeloma, or leukemia), or in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease) are at an increased risk. Tadalafil has vasodilatory properties that may result in transient decreases in blood pressure. Patients with preexisting hypotension,with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Should signs of pulmonary edema occur when tadalafil tablets are administered, the possibility of associated PVOD should be considered. When used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including tadalafil. Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil.

8.1 Pregnancy

Should signs of pulmonary edema occur when tadalafil tablets are administered, the possibility of associated PVOD should be considered.5.3 Visual LossWhen used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including tadalafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking. Based on published literature, the annual incidence of NAION is 2.5 to 11.8 cases per 100,000 in males aged ≥50 in the general population. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, typical of erectile dysfunction treatment, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20).

Tadalafil may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended.5.4 Hearing ImpairmentCases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions ( 6.2)] .5.5 Combination with Other PDE5 InhibitorsTadalafil is also marketed for erectile dysfunction. The safety and efficacy of taking tadalafil tablets together with another PDE5 inhibitors has not been studied. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors.5.6 Prolonged ErectionThere have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. Patients who have conditions that might predispose them to priapism (such as without prescription cialis soft sickle cell anemia, multiple myeloma, or leukemia), or in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease) are at an increased risk.

What are the most common side effects of tadalafil?

Tadalafil has vasodilatory properties that may result in transient decreases in blood pressure. Patients with preexisting hypotension,with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Should signs of pulmonary edema occur when tadalafil tablets are administered, the possibility of associated PVOD should be considered. When used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions ( 6.2)] . Tadalafil is also marketed for erectile dysfunction.

• The yellow Cialis pill is often marketed with medical claims about ED treatment.
• Online ordering of yellow Cialis should be done cautiously to avoid scams.
• Yellow Cialis is used by men seeking a reliable solution for ED.
• The pill's color helps distinguish it from other ED medications like Viagra.
• Dosage adjustments for yellow Cialis depend on individual health factors.
• The yellow Cialis pill can be taken on an empty stomach for quicker results.
• The safety profile of yellow Cialis has been established through clinical trials.
• Cialis, including the yellow dosage form, is prescribed worldwide.
• Regular monitoring by a healthcare provider enhances safe use of yellow Cialis.
• The yellow Cialis pill is an effective, long-lasting option for ED.
• Potential interactions with other medications should be managed under medical advice.
• The yellow Cialis pill is a widely trusted medication for ED management.

Inform patients taking tadalafil tablets not to take other PDE5 inhibitors. There have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. 6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling:Hypotension [see Warnings and Precautions ( 5.1)]Visual Loss [see Warnings and Precautions ( 5.3) and Patient Counseling Information ( 17)]Hearing loss [see Warnings and Precautions ( 5.4)]Priapism [see Warnings and Precautions ( 5.6)]6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. In trials of tadalafil tablets, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. The overall rates of discontinuation because of an adverse event (AE) in the placebo-controlled trial were 9% for tadalafil tablets 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil tablets 40 mg was 4% compared to 5% in placebo-treated patients.In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of tadalafil.